Eloralintide is an experimental once-weekly injection from Eli Lilly. It is not a GLP-1 drug, despite being listed as one almost everywhere — it works on a different hormone called amylin. In its phase 2 trial it produced 20% weight loss over 48 weeks, and it is not approved anywhere.
The short version
| What it is | An experimental weekly injection for weight management |
| Also called | LY3841136 |
| Maker | Eli Lilly |
| Class | Amylin receptor agonist — not a GLP-1 |
| Status | Not approved. In phase 3 trials |
| Best result | 20% mean weight loss at 48 weeks (phase 2) |
| Can you get it? | No |
What amylin is, and why it is not GLP-1
Your pancreas releases two hormones when you eat. Insulin is the famous one. Amylin is released alongside it, and its job is different: it slows how quickly the stomach empties and tells the brain you have had enough.
GLP-1 is a third hormone, from the gut rather than the pancreas, doing a partly overlapping job through its own receptors. Every approved weight-loss drug — Ozempic, Wegovy, Mounjaro, Zepbound, Foundayo — works on the GLP-1 receptor.
Eloralintide works on the amylin receptor instead. Same destination, different road.
Why that distinction matters practically
It is not pedantry. Three things follow from it.
It can be combined rather than swapped. Two drugs aimed at the same receptor compete for it; two aimed at different receptors can add up. Eloralintide is being trialled alongside tirzepatide for exactly this reason, and CagriSema already pairs an amylin analogue with semaglutide.
It is an option for people GLP-1s do not suit. Someone who could not tolerate semaglutide is not obviously going to fail on a drug that works elsewhere.
The side effects differ. Eloralintide's fatigue rates ran 43 to 46% at the top doses, well above what GLP-1 drugs report, while its nausea at the same doses was lower than Wegovy's. A different pathway brings a different trade rather than a better one.
What the trial found
A 48-week phase 2 published in the Lancet, 263 adults with obesity or overweight plus a weight-related condition. Mean weight loss at the top dose was 20%, against 0.4% on placebo.
For scale, semaglutide reaches about 14.9% and tirzepatide about 20.9% in their own trials. Eloralintide matched tirzepatide in twenty-four fewer weeks — from a much smaller phase 2 trial, and phase 2 results often come down at scale.
The trial also found something useful about how to take it: nausea depended more on the dose people started at than the dose they finished at. The arm climbing gradually from 3 mg reached 16% weight loss with 25% nausea, while the arm sitting at a fixed 6 mg reached 18% with 64%. Details in eloralintide weight loss.
Can you take it? No
Eloralintide has not been approved by any regulator. No doctor can prescribe it and no pharmacy can dispense it. It is in phase 3 and recruiting, so enrolling in a trial is the only legitimate route — a conversation for a clinician.
Anything sold online under the name carries the problems every unapproved peptide does: unverified identity, unverified strength, nobody accountable. When three vials of another unapproved molecule were analysed, they contained between half and nearly double their labelled dose.
Where to go next
The full eloralintide guide covers the trial, the mechanism and where the programme stands. Eloralintide side effects has the per-arm figures. And if you want something available today, the approved drugs are ranked in the best GLP-1 for weight loss.
Against the drugs you can get
Three comparisons, each with its caveats: vs Zepbound, vs Wegovy and vs Ozempic.
Scientific References
2 sources- 1
Billings LK, Hsia S, Bays H, et al.
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2 randomised trial
The Lancet · 406(10520) · 2025PMID: 41207310
- 2
U.S. National Library of Medicine
ClinicalTrials.gov — eloralintide (LY3841136): 16 registered studies, maximum phase 3, recruiting, lead sponsor Eli Lilly; read 13 August 2026
ClinicalTrials.gov · 2026
References open in a new tab. Content is reviewed against peer-reviewed literature as part of our editorial policy.
About the author
Editor, Modern Weight Science
Claudiu Gheorghe is the editor of Modern Weight Science. He is not a physician. His role is to synthesize peer-reviewed studies, clinical-trial data, and FDA prescribing information into clear, plain-language explanations, and to make sure every factual claim on the site traces back to a cited source. Any decision about starting, changing, or stopping a medication belongs with a licensed clinician who knows your history.
Every claim is checked against peer-reviewed research through our review process and fact-checking policy.
Frequently Asked Questions
What is eloralintide?
An experimental once-weekly injection from Eli Lilly, known in trials as LY3841136, developed for weight management. It activates the amylin receptor — amylin is a hormone released by the pancreas alongside insulin that slows gastric emptying and signals fullness. It is in phase 3 and is not approved anywhere.
Is eloralintide a GLP-1 drug?
No, though it is listed as one almost everywhere. Every approved weight-loss drug works on the GLP-1 receptor; eloralintide works on the amylin receptor, a different hormone from a different organ. The effect is similar and the mechanism is not, which is why it can be combined with a GLP-1 rather than competing with one.
How much weight loss does eloralintide cause?
In its 48-week phase 2 trial, 20% mean weight loss at the top dose against 0.4% on placebo, in 263 people. That matches tirzepatide's roughly 20.9% in twenty-four fewer weeks, and exceeds semaglutide's 14.9% — though from a much smaller phase 2 trial, and phase 2 figures often soften at scale.
Can eloralintide be taken with Zepbound or Wegovy?
That is being tested. Because it targets a different receptor, it can be added rather than swapped — trials of eloralintide with tirzepatide are registered, and CagriSema already pairs an amylin analogue with semaglutide on the same logic. No combination results have been published.
When will eloralintide be available?
There is no approval date. The programme has reached phase 3 with sixteen registered studies and no phase 3 results have been published. A manufacturer files after its pivotal trials report and a regulator then takes its own time, so any date in circulation is a projection.
Continue learning
Where to read next
Not medical advice. This guide is for general education only. GLP-1 medications, dosing, and treatment suitability are decisions for you and a licensed clinician who knows your full medical history.